JEMFRAXTA
Live / Allowed — Second extension granted (statement of use) (as of 29 May 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 10 Sept 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98743162
- Mark type
- Word mark
- Filed
- 10 Sept 2024
- Published for opposition
- 08 Apr 2025
- Attorney of record
- Keith Toms, Esq.
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations for the treatment of mitochondrial disorders; pharmaceutical preparations and substances for treatment of genetic diseases; pharmaceutical preparations for the treatment of diseases or dysfunction of the mitochondria; pharmaceutical preparations featuring cell penetrating peptides for use in the treatment of genetic disorders; pharmaceuticals that treat genetic diseases by use of carrier proteins; pharmaceutical preparations for the treatment of ataxia; pharmaceutical preparations for the treatment of Friedreich's Ataxia; pharmaceutical preparations for protein replacement therapy; pharmaceutical preparations for frataxin replacement therapy
Owner
- Larimar Therapeutics, Inc., Bala Cynwyd, PA, US
- Larimar Therapeutics, Inc., Bala Cynwyd, PA, US
Prosecution history
- 30 May 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 May 2026 — SOU EXTENSION 2 GRANTED
- 29 May 2026 — SOU EXTENSION 2 FILED
- 29 May 2026 — SOU TEAS EXTENSION RECEIVED
- 02 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Dec 2025 — SOU EXTENSION 1 GRANTED
- 01 Dec 2025 — SOU EXTENSION 1 FILED
- 01 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Jun 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 08 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Apr 2025 — PUBLISHED FOR OPPOSITION
- 02 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 17 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 17 Mar 2025 — EXAMINER'S AMENDMENT ENTERED
- 17 Mar 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED